新型冠状病毒肺炎治疗药物研究进展

doi:10.19803/j.1672-8629.20210509

摘要/Abstract

摘要： 2019年新型冠状病毒肺炎（COVID-19）疫情出现以来,其预防和治疗成为国内外最热门的领域之一。该疾病是由严重急性呼吸系统综合征冠状病毒2型—新型冠状病毒（SARS-CoV-2）引起的呼吸道传染性疾病,严重危害人类的身体健康和生命安全,因此对其相关治疗药物的发现和研究尤为重要。本文从SARS-CoV-2治疗药物的靶点、相关化学药物、相关中草药单体对SARS-CoV-2的靶向作用等方面进行文献整理、分析并归纳总结,阐述SARS-CoV-2治疗药物的研究现状,为新药研发及临床治疗应用提供线索。

关键词: 新型冠状病毒, 新型冠状病毒肺炎, 抗病毒药物, 药物作用靶点, 化学药, 中草药单体

Abstract: Since the outbreak of the Corona Virus Disease 2019 (COVID-19) in 2019, its prevention and treatment have become one of the most popular fields at home and abroad. It is a respiratory infectious disease caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), which seriously endangers human health and life safety, so the discovery and research of its related drugs is especially important. This paper analyzed and summarized the targets of SARS-CoV-2 therapeutic drugs, related chemical drugs, and the targeting effects of related Chinese herbal medicine monomers. Particularly, the research status of COVID-19 treatment drugs were reviewed in order to provide clue for follow-up studies.

Key words: SARS-CoV-2, COVID-19, anti-viral drug, drug targetings, chemical medicine, herbal monomer

中图分类号:

R974
R978

李天钰, 贾翌江, 王玉记, 王金辉, 李烨. 新型冠状病毒肺炎治疗药物研究进展[J]. 中国药物警戒, 2022, 19(11): 1266-1271.

LI Tianyu, JIA Yijiang, WANG Yuji, WANG Jinhui, LI Ye. Research progress of treatment drugs for SARS-CoV-2[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1266-1271.

参考文献

[1] YANG JM, REN H, SUN Y, et al.Analysis and reflection on the transmission routes of SARS-CoV-2[J]. Journal of Xi’an Jiaotong University[Medical Sciences)(西安交通大学学报(医学版)], 2020, 41(4): 497-501.
[2] WANG Y.The exploration of new inhibitors for SARS-CoV-2 envelope protein[D]. Shanghai: Shanghai Institutes of Materia Medica, CAS, 2021.
[3] ZHOU P, YANG XL, WANG XG, et al.A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273.
[4] ZHAO J, XU LJ, ZHANG BY, et al.Research progress on drugs for the treatment of COVID-19[J]. Chinese Pharmacological Bulletin(中国药理学通报), 2020, 36(12): 1629-1636.
[5] YUAN K, XIAO XH.Medication selection for clinical treatment of COVID-19[J]. Genomics and Applied Biology(基因组学与应用生物学), 2020, 39(6): 2902-2906.
[6] MA YX, WANG N, WANG B, et al.Structural analysis and stability of arbidol hydrochloride, a treatment drug for COVID-19[J]. Chemical Industry Times(化工时刊), 2020, 34(12): 1-6.
[7] VADUGANATHAN M, VARDENY O, MICHEL T, et al.Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19[J]. The New England Journal of Medicine, 2020, 382(17): 1653-1659.
[8] WRAPP D, WANG N, CORBETT KS, et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483): 1260-1263.
[9] WANG ML, CAO RY, ZHANG LK, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus ( 2019-nCoV) in vitro[J]. Cell Research, 2020, 30: 269-271.
[10] GAUTRET P, LAGIER JC, PAROLA P, et al.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial[J]. International Journal of Antimicrobial Agents, 2020, 56(1): 105949.
[11] PHILIPPE G, JEAN-CHRISTOPHE L, PHILIPPE P, et al.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial[J]. International Journal of Antimicrobial Agents, 2020, 56(1): 105949.
[12] MARKUS H, HANNAH K, SIMON S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.
[13] XU XY, CAO XS, LONG Q, et al.Potential monomer compounds for treatment of corona virus disease 2019(COVID-19) by transmembrane serine proteinase 2(TMPRSS2)[J]. Drug Evaluation Research(药物评价研究), 2020, 43(5): 813-821.
[14] HIMANSHU R, ATANU B, YASH PS, et al.Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19[J]. Molecular Diversity, 2021, 25(3): 1905-1927.
[15] WANG YM, ZHANG DY, DU GH, et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial[J]. The Lancet, 2020, 395(10236): 1569-1578.
[16] GILLENWATER S, RAHAGHI F, HADEH A.Remdesivir for the treatment of COVID-19 — preliminary report[J]. The New England Journal of Medicine, 2020, 383(10): 992-994.
[17] ZHAO CQ, JIN ZH, WANG XF, et al.Current status and advances for development of drugs to treat coronavirus disease[J]. Military Medical Journal of Southeast China(东南国防医药), 2021, 23(1): 58-63.
[18] The National Health Commission Office of the PRC, The Office of the National Administration of Traditional Chinese Medicine. Novel coronavirus pneumonia diagnosis and treatment plan ( trial version 9 )[R/OL]. (2022-03-15)[2022-04-01]. http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml.
[19] JOHANNES K, MARK K, MILAN G, et al.Re(I) tricarbonyl complexes as coordinate covalent inhibitors for the SARS-CoV-2 main cysteine protease[J]. Angewandte Chemie International Edition, 2021, 19(60): 10716-10723.
[20] WANG J, LIANG BQ, CHEN YL, et al.A new class of alpha-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities[J]. European Journal of Medicinal Chemistry, 2021, 215: 113267.
[21] TANUJ S, MOHAMMED A, MOHAMMAD HBS, et al.Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19[J]. Saudi Journal of Biological Sciences, 2021, 28(5): 3152-3159.
[22] SUMIT K, PREM PS, CHARU U, et al.Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies[J]. Methods, 2021: 195(11): 44-56.
[23] ZHAI DX, YU CQ, CHEN W.Summary of the Eighth World Conference on Integrated Traditional Chinese and Western Medicine[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2021, 41(1): 126-128.
[24] LU YR, WANG YG, JIAO YQ, et al.Research progress of traditional Chinese medicine syndrome differentiation and treatment of Coronavirus disease 2019[J]. Journal of Traditional Chinese Medicine(中医杂志), 2020, 61(21): 1846-1851.
[25] The National Health Commission Office of the PRC, The Office of the National Administration of Traditional Chinese Medicine. Novel coronavirus pneumonia diagnosis and treatment plan ( trial version 8 )[R/OL]. (2020-08-19)[2022-04-01]. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml.
[26] CAPODICE JL, CHUBAK BM.Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19[J]. Chinese Medicine, 2021, 16(1): 24.
[27] MUHAMMAD SR, FRAZ S, MUHAMMAD AH, et al.Novel coronavirus-2019 (2019-nCoV): perspectives of emergence, prophylaxis and predicted treatment approaches[J]. Pakistan Journal of Pharmaceutical Sciences, 2020, 33(5): 2199-2207.
[28] BAHBAH EI, NEGIDA A, NABET MS.Purposing saikosaponins for the treatment of COVID-19[J]. Med Hypotheses, 2020, 140: 109782.
[29] MANIA JS, JOHNSONA JB, STEEL JC, et al.Natural product-derived phytochemicals as potential agents against coronaviruses: a review[J]. Virus Research, 2020, 284: 197989.
[30] CINATL J, MORGENSTERN B, BAUER G, et al.Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus[J].The Lancet, 2003, 361(9374): 2045-2046.
[31] WANGA ZL, YANG LY.Chinese herbal medicine: fighting SARS-CoV-2 infection on all fronts[J]. Journal of Ethnopharmacology, 2021, 270: 113869.
[32] ZHAO ZY, XIAO YC, XU LQ, et al.Glycyrrhizic acid nanoparticles as antiviral and anti-inflammatory agents for COVID-19 treatment[J]. ACS Applied Materials & Interfaces, 2021, 13(18): 20995-21006.
[33] LUO P, LIU D, LI J.Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19[J]. International Journal of Antimicrobial Agents, 2020, 55(6): 105995.
[34] TIAN X, GAN WF, NIE YS, et al.Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti- SARS- CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis[J]. BMJ Open, 2021, 11(7): e051484.
[35] DING H, DENG WJ, DING LL, et al.Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients[J]. Journal of Medical Virology, 2020, 92(10): 2200-2204.
[36] ZHANGA JL, LIA WX, LI Y, et al.Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism[J]. Phytomedicine, 2021, 85: 153297.
[37] GUAN JW, ZHENG WJ.Clinical observation of tanshinone IIA sulfonate sodium in the treatment of novel coronavirus pneumonia[J]. World Latest Medicine Information(世界最新医学信息文摘), 2020, 20(34): 267-268.
[38] HU SL, WANG J, ZHANG YJ, et al.Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2[J]. Journal of Medical Virology, 2021, 5(93): 3143-3151.
[39] LI JX, HAN DW, SUN LY, et al.Virtual screening the active ingredient and mechanism of Shenmai injection in treatment of novel coronavirus pneumonia based on network pharmacology and high throughput molecular docking[J]. International Journal of Traditional Chinese Medicine(国际中医中药杂志), 2021, 43(1): 54-61.
[40] PATEL CN, GOSWAMI D, JAISWAL DG, et al.Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations[J]. Journal of Molecular Graphics and Modelling, 2021, 105: 107874.
[41] ZENG CC, YUAN ZZ, PAN XQ, et al.Efficacy of traditional Chinese medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: a structured summary of a study protocol for a randomized controlled trial[J]. Trials, 2020, 21(1): 1029.
[42] LYU YN, WANG SS, LIANG PD, et al.Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach[J]. Analytical and Bioanalytical Chemistry, 2021, 413(11): 2995-3004.
[43] LI XL, QIU Q, LI MY, et al.Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19)[J]. Aging (Albany NY), 2021, 4(13): 4811-4830.
[44] CHEN ZN, CUI QH, COOPER L, et al.Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases[J]. Cell & Bioscience, 2021, 11(1): 45.
[45] CAI Y, ZENG M, CHEN YZ.Staged treatment analysis of the network pharmacology based traditional Chinese medicine compound “Three Chinese Patent Medicines, Three Traditional Chinese Medicine Formula” in the treatment of COVID-19[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology(世界科学技术-中医药现代化), 2021, 23(2): 358-384.